Literature DB >> 8482464

Propafenone-induced liver injury: report of a case and review of the literature.

A Mondardini1, P Pasquino, P Bernardi, E Aluffi, B Tartaglino, G Mazzucco, F Bonino, G Verme, F Negro.   

Abstract

A case of an acute cholestatic syndrome associated with use of the antiarrhythmic drug propafenone is reported here. The close time relationship between the administration of the drug and the acute onset of the liver damage, the histological findings, and the reappearance of biochemical signs of liver dysfunction upon rechallenge with the same medication strongly suggest that propafenone was involved in the pathogenesis of this syndrome. Although rare, hepatotoxicity from this widely used antiarrhythmic medication should be kept in mind in the differential diagnosis of sudden cholestatic syndrome of obscure origin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482464     DOI: 10.1016/0016-5085(93)90365-j

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  4 in total

Review 1.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

2.  Propafenone hepatotoxicity: report of two new cases.

Authors:  Daniel Cocozzella; José Curciarello; Osvaldo Corallini; Adriana Olivera; María Malca Alburquerque; Emilio Fraquelli; Liliana Zamagna; Alejandro Olenchuck; Alberto Cremona
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

3.  Antiarrhythmic agents and the risk of malignant neoplasm of liver and intrahepatic bile ducts.

Authors:  Yun-Ping Lim; Cheng-Li Lin; Yen-Ning Lin; Wei-Chih Ma; Wei-Cheng Chen; Dong-Zong Hung; Chia-Hung Kao
Journal:  PLoS One       Date:  2015-01-15       Impact factor: 3.240

Review 4.  Propafenone hepatotoxicity: report of a new case and review of the literature.

Authors:  Lara B Younan; Kassem A Barada; Walid G Faraj; Ayman N Tawil; Mark N Jabbour; Maurice Y Khoury; Nadim Mw El-Majzoub; Mohamad A Eloubeidi
Journal:  Saudi J Gastroenterol       Date:  2013 Sep-Oct       Impact factor: 2.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.